Fifth Third Bancorp grew its holdings in Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) by 28.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 676 shares of the biotechnology company's stock after purchasing an additional 150 shares during the period. Fifth Third Bancorp's holdings in Axon Enterprise were worth $93,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in the company. Highland Capital Management LLC lifted its stake in shares of Axon Enterprise by 4.8% in the 1st quarter. Highland Capital Management LLC now owns 15,971 shares of the biotechnology company's stock valued at $2,200,000 after purchasing an additional 732 shares during the last quarter. Waypoint Capital Advisors LLC acquired a new position in shares of Axon Enterprise in the 1st quarter valued at $1,363,000. State of Alaska Department of Revenue lifted its stake in Axon Enterprise by 1.3% during the 1st quarter. State of Alaska Department of Revenue now owns 9,636 shares of the biotechnology company's stock worth $1,327,000 after acquiring an additional 120 shares in the last quarter. Yarbrough Capital LLC lifted its stake in Axon Enterprise by 28.8% during the 1st quarter. Yarbrough Capital LLC now owns 2,207 shares of the biotechnology company's stock worth $304,000 after acquiring an additional 494 shares in the last quarter. Finally, Baldwin Brothers LLC MA acquired a new position in Axon Enterprise during the 1st quarter worth about $62,000. 72.06% of the stock is currently owned by institutional investors and hedge funds.
Get Axon Enterprise alerts:AXON has been the topic of several research reports. Robert W. Baird decreased their target price on Axon Enterprise from $145.00 to $125.00 in a research note on Wednesday, May 11th. Morgan Stanley lowered Axon Enterprise from an "overweight" rating to an "equal weight" rating and set a $120.00 target price on the stock. in a research note on Monday, May 23rd. Credit Suisse Group initiated coverage on Axon Enterprise in a research note on Monday, May 9th. They set an "outperform" rating and a $169.00 target price on the stock. StockNews.com raised Axon Enterprise from a "hold" rating to a "buy" rating in a research note on Saturday, June 18th. Finally, Northland Securities decreased their target price on Axon Enterprise from $180.00 to $130.00 in a research note on Thursday, May 12th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $172.89.
Shares of NASDAQ AXON opened at $96.85 on Monday. Axon Enterprise, Inc. has a 1-year low of $82.49 and a 1-year high of $209.00. The company has a market cap of $6.88 billion, a price-to-earnings ratio of 186.25 and a beta of 0.61. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.43 and a quick ratio of 2.18. The stock's 50-day moving average is $94.77 and its two-hundred day moving average is $118.06.Axon Enterprise (NASDAQ:AXON – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported $0.76 EPS for the quarter. Axon Enterprise had a return on equity of 3.90% and a net margin of 4.62%. The business had revenue of $256.43 million for the quarter, compared to the consensus estimate of $233.57 million. During the same quarter in the prior year, the business posted ($0.75) EPS. The business's revenue for the quarter was up 31.5% on a year-over-year basis. Equities research analysts anticipate that Axon Enterprise, Inc. will post 1.35 earnings per share for the current fiscal year.
In other news, Director Mark W. Kroll sold 3,159 shares of the stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $102.82, for a total value of $324,808.38. Following the transaction, the director now owns 13,691 shares in the company, valued at approximately $1,407,708.62. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 6.90% of the company's stock.
About Axon Enterprise (Get Rating)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
- Get a free copy of the StockNews.com research report on Axon Enterprise (AXON)
- Five Below Stock is a Recession Play
- Here's How to Dollar Cost Average into Positions in a Bear Market
- MarketBeat: Week in Review 7/4 – 7/8
- Levi Strauss Proves Resilient For Dividend Investors
- AT&T (NYSE:T) Is Its Cheaper Valuation Worth A Buy?
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.